Fortress Biotech Net Income Over Time
| FBIO Stock | USD 3.27 0.34 11.60% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Fortress Biotech Performance and Fortress Biotech Correlation. Will Biotechnology sector continue expanding? Could Fortress diversify its offerings? Factors like these will boost the valuation of Fortress Biotech. Market participants price Fortress higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fortress Biotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.205 | Return On Assets | Return On Equity |
Fortress Biotech's market price often diverges from its book value, the accounting figure shown on Fortress's balance sheet. Smart investors calculate Fortress Biotech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Fortress Biotech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Fortress Biotech and related stocks such as XBiotech, Nutriband, and Vaxart Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XBIT | (15.2 M) | (15.2 M) | (15.2 M) | (9.9 M) | (21.7 M) | (37.5 M) | (52.8 M) | (33.1 M) | (21.1 M) | 668.6 M | (11.2 M) | (17.4 M) | (32.9 M) | (24.6 M) | (38.5 M) | (44.3 M) | (42.1 M) |
| NTRB | (400) | (400) | (400) | (400) | (400) | (400) | (151.3 K) | (2.7 M) | (3.3 M) | (2.8 M) | (3.2 M) | (8.4 M) | (4.8 M) | (5.5 M) | (10.5 M) | (9.4 M) | (9 M) |
| VXRT | 1000 K | (4.5 M) | (8.7 M) | (8.9 M) | (11 M) | (19.1 M) | (25.4 M) | (12.5 M) | (18 M) | (18.6 M) | (32.2 M) | (70.5 M) | (107.8 M) | (82.5 M) | (66.9 M) | (60.3 M) | (57.2 M) |
| CRVO | 200 K | (22.6 M) | (6.9 M) | (2.5 M) | (14.4 M) | (6.7 M) | (18 M) | (1.4 M) | (18.4 M) | (11.8 M) | (14.2 M) | (24.1 M) | (15.6 M) | (2.2 M) | (16.3 M) | (14.7 M) | (13.9 M) |
| ADAG | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (17.3 M) | (16.4 M) | (73.2 M) | (80 M) | (18.9 M) | (33.4 M) | (30.1 M) | (31.6 M) |
| RLMD | (12.1 K) | (12.1 K) | (12.1 K) | (45 K) | (20.8 M) | (20.8 M) | (3 M) | (6.3 M) | (9 M) | (15 M) | (59.5 M) | (125.8 M) | (157 M) | (98.8 M) | (80 M) | (72 M) | (75.6 M) |
| GANX | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.2 M) | (3.6 M) | (13.9 M) | (17.6 M) | (22.3 M) | (20.4 M) | (18.4 M) | (19.3 M) |
| TCRX | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (26.1 M) | (48.6 M) | (66.2 M) | (89.2 M) | (127.5 M) | (114.7 M) | (109 M) |
| IMUX | (5.9 M) | (5.9 M) | (6.7 M) | (32.7 M) | (47.7 M) | (52 M) | (41 M) | (52.1 M) | (41.5 M) | (34.8 M) | (44 M) | (92.8 M) | (120.4 M) | (93.6 M) | (100.5 M) | (90.5 M) | (85.9 M) |
| PMVP | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (25.4 M) | (34.4 M) | (57.8 M) | (73.3 M) | (69 M) | (58.7 M) | (52.8 M) | (55.5 M) |
Fortress Biotech and related stocks such as XBiotech, Nutriband, and Vaxart Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Fortress Biotech financial statement analysis. It represents the amount of money remaining after all of Fortress Biotech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Fortress Biotech | FBIO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1111 Kane Concourse, |
| Exchange | NASDAQ Exchange |
USD 3.27
Check out Fortress Biotech Performance and Fortress Biotech Correlation. To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Fortress Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.